论文部分内容阅读
目的:探讨腹腔热灌注联合静脉化疗治疗晚期卵巢癌的疗效及不良反应。方法:将2005年5月～2009年2月收治的90例经病理学或细胞学确诊的Ⅲ～Ⅳ期卵巢癌患者采用信封法随机分为腹腔热灌注联合静脉化疗组50例(治疗组)和单纯静脉化疗组40例(对照组),治疗组采用顺铂腹腔热灌注联合紫杉醇静脉化疗,对照组采用紫杉醇联合顺铂静脉化疗,观察两组的肿瘤控制率、腹水控制率及不良反应。结果:两组的肿瘤控制率(CR+PR)分别为72%和47.5%,差异具有统计学意义(P=0.018),两组的腹水控制率(CR+PR)分别为80%和50%,差异具有统计学意义(P=0.014),两组Ⅲ～Ⅳ度不良反应发生率分别为38%和40%,差异无统计学意义(P=0.847)。结论:腹腔热灌注联合静脉化疗治疗晚期卵巢癌的疗效优于单纯静脉化疗,且不良反应能够耐受,值得临床推广。
Objective: To investigate the efficacy and adverse reactions of intraperitoneal hyperthermic perfusion combined with intravenous chemotherapy in the treatment of advanced ovarian cancer. Methods: Ninety patients with pathologically or cytologically diagnosed stage III-IV ovarian cancer who were admitted to our hospital from May 2005 to February 2009 were randomly divided into 50 cases (treated group) by intraperitoneal hyperthermic perfusion combined with intravenous chemotherapy. (Control group). The treatment group was treated with cisplatin intraperitoneal hyperthermic perfusion combined with paclitaxel intravenous chemotherapy. The control group was treated with paclitaxel combined with cisplatin intravenous chemotherapy. The tumor control rate, ascites control rate and adverse reactions in both groups were observed. Results: The tumor control rates (CR + PR) were 72% and 47.5% in both groups (P = 0.018). The ascites control rates (CR + PR) were 80% and 50% , The difference was statistically significant (P = 0.014). The incidence of grade Ⅲ ~ Ⅳ adverse reactions in both groups were 38% and 40%, respectively, with no significant difference (P = 0.847). Conclusion: Intraperitoneal hyperthermic perfusion combined with intravenous chemotherapy is superior to simple intravenous chemotherapy in treatment of advanced ovarian cancer, and adverse reactions are tolerable, which is worthy of clinical promotion.